The Pre-Ablation Circulating Tumor-Associated Inflammatory Index Predicts the Prognosis of Patients with Liver Metastasis from Pancreatic Cancer

References

• Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71(1):7–33. doi:10.3322/caac.21654
   PubMed Web of Science ®Google Scholar
• Khalaf N, El-Serag HB, Abrams HR, Thrift AP. Burden of pancreatic cancer: from epidemiology to practice. Clin Gastroenterol Hepatol. 2021;19(5):876–884. doi:10.1016/j.cgh.2020.02.054
   PubMed Web of Science ®Google Scholar
• Gupta R, Amanam I, Chung V. Current and future therapies for advanced pancreatic cancer. J Surg Oncol. 2017;116(1):25–34. doi:10.1002/jso.24623
   PubMed Web of Science ®Google Scholar
• Liu M, Wang M, Li S. Prognostic factors of survival in pancreatic cancer metastasis to liver at different ages of diagnosis: a SEER population-based cohort study. Front Big Data. 2021;4:654972. doi:10.3389/fdata.2021.654972
   PubMedGoogle Scholar
• Oweira H, Petrausch U, Helbling D, et al. Prognostic value of site-specific metastases in pancreatic adenocarcinoma: a Surveillance Epidemiology and End Results database analysis. World J Gastroenterol. 2017;23(10):1872–1880. doi:10.3748/wjg.v23.i10.1872
   PubMed Web of Science ®Google Scholar
• Qian L, Shen Y, Xie J, Meng Z. Immunomodulatory effects of ablation therapy on tumors: potentials for combination with immunotherapy. Biochim Biophys Acta Rev Cancer. 2020;1874(1):188385. doi:10.1016/j.bbcan.2020.188385
   PubMed Web of Science ®Google Scholar
• Yousaf MN, Ehsan H, Muneeb A, et al. Role of radiofrequency ablation in the management of unresectable pancreatic cancer. Front Med. 2020;7:624997. doi:10.3389/fmed.2020.624997
   Web of Science ®Google Scholar
• Tranberg K-G. Local destruction of tumors and systemic immune effects. Front Oncol. 2021;11:708810. doi:10.3389/fonc.2021.708810
   PubMed Web of Science ®Google Scholar
• Schneider T, Sevko A, Heussel CP, et al. Serum inflammatory factors and circulating immunosuppressive cells are predictive markers for efficacy of radiofrequency ablation in non-small-cell lung cancer. Clin Exp Immunol. 2015;180(3):467–474. doi:10.1111/cei.12596
   PubMed Web of Science ®Google Scholar
• Park JB, Kim YH, Kim J, et al. Radiofrequency ablation of liver metastasis in patients with locally controlled pancreatic ductal adenocarcinoma. J Vasc Interv Radiol. 2012;23(5):635–641. doi:10.1016/j.jvir.2012.01.080
   PubMed Web of Science ®Google Scholar
• Yan X, Ning Z-Y, Wang P, et al. Combined ablation-chemotherapy versus chemotherapy alone for pancreatic cancer with liver metastasis: a propensity score matching study. Expert Rev Gastroenterol Hepatol. 2021;15(9):1047–1056. doi:10.1080/17474124.2021.1869937
   PubMed Web of Science ®Google Scholar
• Yako YY, Kruger D, Smith M, Brand M. Cytokines as biomarkers of pancreatic ductal adenocarcinoma: a systematic review. PLoS One. 2016;11(5):e0154016. doi:10.1371/journal.pone.0154016
   PubMed Web of Science ®Google Scholar
• Hu B, Yang X-R, Xu Y, et al. Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma. Clin Cancer Res. 2014;20(23):6212–6222. doi:10.1158/1078-0432.CCR-14-0442
   PubMed Web of Science ®Google Scholar
• Zhang K, Hua Y-Q, Wang D, et al. Systemic immune-inflammation index predicts prognosis of patients with advanced pancreatic cancer. J Transl Med. 2019;17(1):30. doi:10.1186/s12967-019-1782-x
   PubMed Web of Science ®Google Scholar
• Li Y, Wang J, Wang H, Zhang S, Wei Y, Liu S. The interplay between inflammation and stromal components in pancreatic cancer. Front Immunol. 2022;13:850093. doi:10.3389/fimmu.2022.850093
   PubMed Web of Science ®Google Scholar
• Hamada S, Masamune A, Shimosegawa T. Inflammation and pancreatic cancer: disease promoter and new therapeutic target. J Gastroenterol. 2014;49(4):605–617. doi:10.1007/s00535-013-0915-x
   PubMed Web of Science ®Google Scholar
• Shi L, Chen L, Wu C, et al. PD-1 blockade boosts radiofrequency ablation-elicited adaptive immune responses against tumor. Clin Cancer Res. 2016;22(5):1173–1184. doi:10.1158/1078-0432.CCR-15-1352
   PubMed Web of Science ®Google Scholar
• Fei Q, Pan Y, Lin W, et al. High-dimensional single-cell analysis delineates radiofrequency ablation induced immune microenvironmental remodeling in pancreatic cancer. Cell Death Dis. 2020;11(7):589. doi:10.1038/s41419-020-02787-1
   PubMed Web of Science ®Google Scholar
• Abbas AK, Trotta E, Simeonov RD, Marson A, Bluestone JA. Revisiting IL-2: biology and therapeutic prospects. Sci Immunol. 2018;3(25). doi:10.1126/sciimmunol.aat1482
   PubMed Web of Science ®Google Scholar
• Barata JT, Durum SK, Seddon B. Flip the coin: IL-7 and IL-7R in health and disease. Nat Immunol. 2019;20(12):1584–1593. doi:10.1038/s41590-019-0479-x
   PubMed Web of Science ®Google Scholar
• Zhang M, Huang L, Ding G, et al. Interferon gamma inhibits CXCL8-CXCR2 axis mediated tumor-associated macrophages tumor trafficking and enhances anti-PD1 efficacy in pancreatic cancer. J Immunother Cancer. 2020;8(1):e000308. doi:10.1136/jitc-2019-000308
   PubMed Web of Science ®Google Scholar
• Moosavi F, Giovannetti E, Saso L, Firuzi O. HGF/MET pathway aberrations as diagnostic, prognostic, and predictive biomarkers in human cancers. Crit Rev Clin Lab Sci. 2019;56(8):533–566. doi:10.1080/10408363.2019.1653821
   PubMed Web of Science ®Google Scholar
• Pothula SP, Xu Z, Goldstein D, Pirola RC, Wilson JS, Apte MV. Targeting HGF/c-MET axis in pancreatic cancer. Int J Mol Sci. 2020;21(23):9170. doi:10.3390/ijms21239170
   PubMed Web of Science ®Google Scholar
• Papaccio F, Della Corte CM, Viscardi G, et al. HGF/MET and the immune system: relevance for cancer immunotherapy. Int J Mol Sci. 2018;19(11):3595. doi:10.3390/ijms19113595
   PubMed Web of Science ®Google Scholar
• Yuan C, Morales-Oyarvide V, Khalaf N, et al. Prediagnostic inflammation and pancreatic cancer survival. J Natl Cancer Inst. 2021;113(9):1186–1193. doi:10.1093/jnci/djab040
   PubMedGoogle Scholar
• Dong M, Shi Y, Yang J, et al. Prognostic and clinicopathological significance of systemic immune-inflammation index in colorectal cancer: a meta-analysis. Ther Adv Med Oncol. 2020;12:1758835920937425. doi:10.1177/1758835920937425
   Web of Science ®Google Scholar
• Zhu M, Chen L, Kong X, et al. The systemic immune-inflammation index is an independent predictor of survival in breast cancer patients. Cancer Manag Res. 2022;14:775–820. doi:10.2147/CMAR.S346406
   PubMed Web of Science ®Google Scholar
• Chen L, Yan Y, Zhu L, et al. Systemic immune-inflammation index as a useful prognostic indicator predicts survival in patients with advanced gastric cancer treated with neoadjuvant chemotherapy. Cancer Manag Res. 2017;9:849–867. doi:10.2147/CMAR.S151026
   PubMed Web of Science ®Google Scholar
• Jin M, Yuan S, Yuan Y, Yi L. Prognostic and clinicopathological significance of the systemic immune-inflammation index in patients with renal cell carcinoma: a meta-analysis. Front Oncol. 2021;11:735803. doi:10.3389/fonc.2021.735803
   PubMed Web of Science ®Google Scholar
• Alifano M. Systemic immune-inflammation index and prognosis of advanced non-small cell lung cancer. Ann Transl Med. 2020;8(11):667. doi:10.21037/atm.2020.03.174
   PubMed Web of Science ®Google Scholar
• Murthy P, Zenati MS, Al Abbas AI, et al. Prognostic value of the Systemic Immune-Inflammation Index (SII) after neoadjuvant therapy for patients with resected pancreatic cancer. Ann Surg Oncol. 2020;27(3):898–906. doi:10.1245/s10434-019-08094-0
   PubMed Web of Science ®Google Scholar
• Shang J, Han X, Zha H, et al. Systemic immune-inflammation index and changes of neutrophil-lymphocyte ratio as prognostic biomarkers for patients with pancreatic cancer treated with immune checkpoint blockade. Front Oncol. 2021;11:585271. doi:10.3389/fonc.2021.585271
   PubMed Web of Science ®Google Scholar